Company Overview and News

8
Cost-Saving Initiatives to Boost Ameris Bancorp's Efficiency

2018-09-24 zacks
Ameris Bancorp (ABCB - Free Report) has announced its plans to undertake cost-saving initiatives in a bid to lower annual operating expenses. As part of its efforts, the company intends to consolidate certain branches and trim data-processing fees. These efforts will help the bank slash costs by $20 million in 2019. These initiatives will enable Ameris Bancorp to reinvest the savings for achieving its long-term growth targets without impacting earnings in 2018 and 2019.
KBH IBTX AFCF FBMS INDB HMBH CBTX IBCP FIBH AMNB ABCB ACFC FBSI

1
First Bancshares Driving A High-Growth Plan Across The Gulf States

2018-09-21 seekingalpha
Although organic loan growth was a little sluggish in the second quarter, the overall pace of growth for First Bancshares remains robust, with healthy spreads from a low deposit beta.
FIBH SSNF FBSI FBMS

 
Yield on US 10-Year Treasury Note Hits 3%: 5 Top Bank Picks

2018-09-17 zacks
On Sep 14, the yield on benchmark 10-year U.S. Treasury Note crossed 3%. The increase in government bond yield can primarily be attributed to expectations of higher economic growth in the third quarter of 2018. Moreover, job market data for August revealed a significant surge in the hourly wage rate which has once again fanned inflationary apprehensions. Strong fundamentals of the U.S. economy may lead to higher interest rated either in the form of Fed rate hike or higher yields on government bonds.
FAM BHBK BPOP FBMS BPOPP FIBH BPOPO NRIM BMRC BPOPM FBSI BPOPN

 
First Bancshares, Inc. Announces Stock Repurchase Program

2018-08-31 globenewswire
MOUNTAIN GROVE, Mo., Aug. 31, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCPink - FstBksh: FBSI), the holding company for Stockmens Bank (“Bank”), today announced that the Company’s Board of Directors authorized the repurchase of an aggregate of 25,000 shares of the Company’s common stock. The repurchase program will be commenced immediately and will be funded by the Company's available cash.
FIBH FBSI FBMS

10
U.S. Banks Earn Record Profit in Q2: 5 Top-Ranked Picks

2018-08-24 zacks
The first half of 2018 has turned out to be highly profitable for the U.S. banking sector. In the second quarter of 2018, total profit of the banks topped prior record set in the preceding quarter. Moreover, U.S. banks are set to benefit significantly from expected hike in interest rate by the Fed in September. At this stage, it will be a prudent move to invest in bank stocks with favorable Zacks Rank and strong growth potential.
FAM BHBK BPOP FBMS NWL BPOPP FIBH BPOPO BCML NRIM BPOPM FBSI BPOPN

3
Core Inflation Picks Up to a 10-Year High: 5 Winners

2018-08-13 zacks
Cost of living for Americans rose in July at the fastest pace in a decade, indicating a strong U.S. economy and tighter labor market. Shelter costs gave a big boost to results, implying that the Fed's gradual interest rate hike will be on track.
BRK.A FAM PVG FIBH LADR ARI PVG FBSI FBMS

 
StoneCastle Financial (BANX) CEO Josh Siegel on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Greetings and welcome to the StoneCastle Financial Corp. Second Quarter Financial Release Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
FIBH FBSI BANX FBMS

 
First Bancshares, Inc. Announces Second Quarter 2018 Results

2018-07-13 globenewswire
MOUNTAIN GROVE, Mo., July 13, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCPink:FBSI), the holding company for Stockmens Bank (“Bank”), today announced its financial results for the quarter ended June 30, 2018.
FIBH FBSI FBMS

4
First Bancshares, Inc. Announces First Quarter 2018 Results

2018-04-27 globenewswire
MOUNTAIN GROVE, Mo., April 27, 2018 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCQB:FBSI), the holding company for Stockmens Bank (“Bank”), today announced its financial results for the quarter ended March 31, 2018.
FIBH FBSI FBMS

4
First Bancshares, Inc. Reports Operating Results for the Quarter and Year Ended December 31, 2017

2018-04-06 globenewswire
First Bancshares, Inc. (“Company”) (OTCQB:FBSI), the holding company for Stockmens Bank, Colorado Springs, Colorado today announced the Company’s financial results for the quarter and year ended December 31, 2017.
FIBH FBSI FBMS

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

5h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

CUSIP: 318916103